Form D · Pharmaceuticals
Anvion Bio, Inc.
San Diego, CA · CIK 0002158000
Offering snapshot reported Oct 7, 2026 · SEC filing
- Reported sold
- $100K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 22, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 7, 2026 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-600314
Source: Form D, filed Oct 7, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anastasia Bodan | Director |
| Larry Braga | Director, Executive |
| Kevin Ernst | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
6191 Cornerstone Court E. Suite 109
San Diego, CA, 92121
San Diego, CA, 92121